Mitochondrial dysfunction in Alzheimer’s disease - a proteomics perspective

@article{Abyadeh2021MitochondrialDI,
  title={Mitochondrial dysfunction in Alzheimer’s disease - a proteomics perspective},
  author={Morteza Abyadeh and Vivek Kumar Gupta and Nitin Chitranshi and Veer Bala Gupta and Yunqi Wu and Danit Saks and Roshana Wander Wall and Matthew J. Fitzhenry and Devaraj K. Basavarajappa and Yuyi You and Ghasem Hosseini Salekdeh and Paul A. Haynes and Stuart L. Graham and Mehdi Mirzaei},
  journal={Expert Review of Proteomics},
  year={2021},
  volume={18},
  pages={295 - 304}
}
ABSTRACT Mitochondrial dysfunction is involved in Alzheimer’s disease (AD) pathogenesis. Mitochondria have their own genetic material; however, most of their proteins (∼99%) are synthesized as precursors on cytosolic ribosomes, and then imported into the mitochondria. Therefore, exploring proteome changes in these organelles can yield valuable information and shed light on the molecular mechanisms underlying mitochondrial dysfunction in AD. Here, we review AD-associated mitochondrial changes… 
Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease
TLDR
An overview of the importance of mitochondria for maintenance of neuronal function and how mitochondrial dysfunction acts as a driver of cognitive impairment in AD is presented and possible treatments targeting mitochondrial dysfunction as therapeutic approaches for AD are provided.
Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging
TLDR
The functions of mitochondria in cutaneous physiology beyond energy (ATP) and ROS production are examined and the mitochondrial protein MPZL3 as a promising new drug target for future ‘mitochondrial dermatology’ is highlighted.
Vitamin K2 Modulates Organelle Damage and Tauopathy Induced by Streptozotocin and Menadione in SH-SY5Y Cells
TLDR
Results suggested that vitamin K2 alleviated mitochondrial damage, ER stress and tauopathy-mediated neuronal cell death, which highlights its role as new antioxidative therapeutics targeting related cellular processes.
iTRAQ-Based Proteomics Analysis of Rat Cerebral Cortex Exposed to Valproic Acid before Delivery.
TLDR
It is found that increased expression of DEPs was associated with energy metabolism in the cerebral cortex of VPA rats, implying that ASD may be a distinct type of mitochondrial dysfunction that requires further investigation.
A Proteomic View of Cellular and Molecular Effects of Cannabis
TLDR
This review provides a comprehensive overview of both in vitro and in vivo proteomic studies involving the cellular and molecular effects of cannabis and cannabis-derived compounds to understand fully its implications as a pharmaceutical drug.
Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
TLDR
This work has reviewed several AD clinical studies and summarized the experience to date with Aducanumab and two other potential AD drugs including Zagotenemab and Pioglitazone, which have shown mixed results so far and the next few years will be critical to elucidate and interpret their broad long-term protective effects.
Key Genes and Biochemical Networks in Various Brain Regions Affected in Alzheimer’s Disease
TLDR
The results provide the foundation for further research investigating the role of these pathways in AD pathogenesis, and potential application of these miRNAs and TFs as therapeutic and diagnostic targets.

References

SHOWING 1-10 OF 117 REFERENCES
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances
TLDR
This review will discuss mechanisms underlying mitochondrial dysfunction with a focus on the loss of mitochondrial structural and functional integrity in AD including mitochondrial biogenesis and dynamics, axonal transport, ER-mitochondria interaction, mitophagy and mitochondrial proteostasis.
Quantitative profiling brain proteomes revealed mitochondrial dysfunction in Alzheimer’s disease
TLDR
The results showed that dysregulated mitochondrial complexes including electron transport chain (ETC) and ATP-synthase are the potential driver for pathology of the AD.
Mitochondrial Dysfunction and Stress Responses in Alzheimer’s Disease
TLDR
Current recognized contributions of the mitochondria to AD are reviewed, with an emphasis on their potential contribution to brain stress responses.
Mitochondrial Molecular Abnormalities Revealed by Proteomic Analysis of Hippocampal Organelles of Mice Triple Transgenic for Alzheimer Disease
TLDR
P perturbations of hippocampus mitochondrial energy metabolism-related proteins responsible for ATP generation via oxidation phosphorylation (OXPHOS), especially nuclear-encoded OXPHOS proteins, correlated with the amyloid-associated cognitive deficits of this murine AD model and may represent novel biomarkers of AD.
Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease.
Mitochondrial Dysfunction in Huntington's Disease.
TLDR
This chapter resumes some of the evidences that pose mitochondria as a main regulatory organelle in HD-affected neurons, uncovering some potentially therapeutic mitochondrial-based relevant targets.
Brain Mitochondria, Aging, and Parkinson’s Disease
TLDR
A tight link exists between mitochondria, aging, and PD and several nuclear genes that are mutated in hereditary PD are usually implicated in mitochondrial functioning to a various extent and their mutation may cause mitochondrial impairment.
Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
TLDR
A detailed analysis of the significance of mitochondrial deterioration in AD and of a pharmacological treatment at this level is performed, as an effective drug treatment in AD is still missing and new therapeutic concepts are urgently needed.
...
...